These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25179738)

  • 1. Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations.
    Yan W; Xuan C; Ma G; Zhang L; Dong N; Wang Z; Xu R
    J Cardiothorac Surg; 2014 Sep; 9():156. PubMed ID: 25179738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
    Končar IB; Davidović LB; Savić N; Sinđelić RB; Ilić N; Dragas M; Markovic M; Kostic D
    J Vasc Surg; 2011 Apr; 53(4):1032-7. PubMed ID: 21215579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
    Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
    Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection.
    Zindovic I; Sjögren J; Ahlsson A; Bjursten H; Fuglsang S; Geirsson A; Ingemansson R; Hansson EC; Mennander A; Olsson C; Pan E; Ullén S; Gudbjartsson T; Nozohoor S
    J Thorac Cardiovasc Surg; 2017 Dec; 154(6):1852-1859.e2. PubMed ID: 28967418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection.
    Grubitzsch H; Vargas-Hein O; Von Heymann C; Konertz W
    J Cardiovasc Surg (Torino); 2009 Aug; 50(4):531-4. PubMed ID: 18948874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity and impact of autologous platelet rich plasma use in acute type A dissection.
    Sandhu HK; Tanaka A; Dahotre S; Charlton-Ouw KM; Miller CC; Estrera AL; Sheinbaum R; Safi HJ; Zhou SF
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2288-2297.e1. PubMed ID: 31519411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis.
    Tritapepe L; De Santis V; Vitale D; Nencini C; Pellegrini F; Landoni G; Toscano F; Miraldi F; Pietropaoli P
    Crit Care Med; 2007 Jul; 35(7):1685-90. PubMed ID: 17522585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
    Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
    Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant activated factor VII for postoperative hemorrhage following repair of acute type A aortic dissection.
    Lehr EJ; Alford TJ; Wang SH
    Heart Surg Forum; 2010 Oct; 13(5):E275-9. PubMed ID: 20961825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding With Cardiac Surgery.
    Katz A; Ahuja T; Arnouk S; Lewis TC; Marsh K; Papadopoulos J; Merchan C
    J Intensive Care Med; 2022 Feb; 37(2):231-239. PubMed ID: 33402016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations.
    Andersen ND; Bhattacharya SD; Williams JB; Fosbol EL; Lockhart EL; Patel MB; Gaca JG; Welsby IJ; Hughes GC
    Ann Thorac Surg; 2012 Jun; 93(6):1921-8; discussion 1928-9. PubMed ID: 22551846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII.
    Tawfick WA; Tawfik S; Hynes N; Mahendran B; Sultan S
    Vascular; 2006; 14(1):32-7. PubMed ID: 16849021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
    Chapman AJ; Blount AL; Davis AT; Hooker RL
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemostatic effectiveness of a new application method for fibrin glue, the "rub-and-spray method", in emergency aortic surgery for acute aortic dissection.
    Minato N; Katayama Y; Yunoki J; Kawasaki H; Satou H
    Ann Thorac Cardiovasc Surg; 2009 Aug; 15(4):265-71. PubMed ID: 19763062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures].
    Koncar IB; Savić N
    Srp Arh Celok Lek; 2008 Sep; 136 Suppl 3():199-203. PubMed ID: 19562868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
    Ekert H; Brizard C; Eyers R; Cochrane A; Henning R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):389-95. PubMed ID: 16788315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery.
    McCall P; Story DA; Karalapillai D
    Can J Anaesth; 2006 Sep; 53(9):926-33. PubMed ID: 16960271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.